menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Bioverativ`s Biologic Enjaymo (sutimlimab) Receives Approval in the U.S.

    FDA

    Bioverativ`s Biologic Enjaymo ( Sutimlimab) Receives Approval in the U.S.

    FDA

    2022 drug approvals: Biopharma delivered 37 new drugs

    FIERCE PHARMA

    Therapeutic-first for cold agglutinin disease haemolytic anaemia

    EUROPEANPHARMACEUTICALREVIEW

    EC approves Enjaymo for treatment of hemolytic anemia

    PRESS RELEASE

    Genzyme`s Enjaymo (sutimlimab) Receives Approval in the Europe

    EMA

    EMA committee recommends Sanofi’s Enjaymo`s approval for haemolytic anaemia

    PHARMABIZ

    CHMP recommends approval of Enjaymo™ (sutimlimab), first and only approved

    PRESS RELEASE

    Bioverativ Therapeutics` Biologic Enjaymo (Sutimlimab) Receives Approval in U.S.

    FDA

    Sanofi`s treatment for rare anemia hits goal in 2nd phase 3

    FIERCE BIOTECH

    Sanofi grapples with rejection of potential first-class orphan drug, faults MFG

    ENDPTS

    FDA issues Complete Response Letter for sutimlimab, an investigational

    PHARMIWEB

    Sanofi gets priority FDA review for sutimlimab product

    REUTERS

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.